Regenerative medicine in Korea

Korea operates one of the most structured regulatory frameworks for advanced regenerative medicine in Asia, and the framework matters in ways that international patients rarely have explained to them at consultation. The Advanced Regenerative Medicine and Advanced Biological Products Safety and Support Act — commonly referenced as the Advanced Regenerative Medicine Act, in force since August 2020 — establishes a tiered designation system for facilities authorised to deliver cell-derived therapies, a classification scheme for the therapies themselves by risk level, and a research-and-clinical-trial pathway that runs parallel to the conventional Korean Ministry of Food and Drug Safety device-and-drug clearance system. Understanding the framework is the difference between booking a substantive regenerative protocol at a designated facility and booking a marketing-driven 'stem cell' package at a clinic whose actual product is a generic exosome topical with no regulatory status. This guide treats the framework at the level a serious international patient should understand: the designation system, the risk-level classification of therapies, the protocols facilities must follow, and the editorial signals that distinguish facilities operating under the Act from clinics borrowing the terminology for marketing purposes. For broader orientation on what 'stem cell' actually denotes in Korean clinical practice, our [stem-cell and exosome guide](/treatments/stem-cell/) covers the bio-active categories; this page covers the regulatory architecture above them, and the broader regenerative-medicine context on our archive partner treats the framework at the level of specific designated facilities.

The Advanced Regenerative Medicine Act and its designation tiers

The Act, enacted in 2020 under joint administration of the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, establishes a designation system for facilities authorised to deliver advanced regenerative medical therapies. The top tier is the Advanced Regenerative Medical Institution designation, awarded to facilities meeting infrastructure, personnel, protocol-documentation, and patient-safety-monitoring requirements. A subset of designated institutions receive a further Advanced Regenerative Medicine Center designation, which carries authority to deliver the highest-risk classification of cell-derived therapy under approved research-trial protocols. The designation system is not symbolic; the Act requires designated facilities to maintain dedicated cell-processing infrastructure, qualified clinical personnel with documented training in regenerative-medicine protocols, an institutional review committee structure, adverse-event reporting protocols, and an audit trail that the Ministry can review at notice. Facilities outside the designation system may not legally deliver therapies that fall within the Act's scope. The Ministry of Health and Welfare framework documentation is the authoritative source on the designation system; the corresponding clinical-trial registry sits under the Ministry of Food and Drug Safety review structure.

Risk-level classification of cell-derived therapies

The Act classifies advanced regenerative therapies into three risk levels, with materially different regulatory pathways for each. Low-risk therapies cover autologous applications where the patient's own cells are processed minimally and returned to the same patient within the same procedural episode; these therapies follow a streamlined notification-and-review pathway and are deliverable at the broader Advanced Regenerative Medical Institution tier. Medium-risk therapies cover autologous applications with substantial cell-processing manipulation, allogeneic applications under controlled conditions, and therapies where the cell product is processed at a separate facility before delivery; these require institutional-review-committee approval, research-protocol registration, and adverse-event monitoring under structured timelines. High-risk therapies cover allogeneic stem-cell applications, genetically modified cell products, and therapies with substantive manipulation beyond conventional clinical practice; these require Advanced Regenerative Medicine Center designation, full clinical-trial-grade protocols, and direct Ministry review of each treatment programme. The classification is not nominal; the risk level governs which facility may deliver the therapy, what consent documentation the patient receives, what aftercare monitoring is required, and what adverse-event reporting protocols apply. International patients booking therapies that nominally sit at medium or high risk should verify the facility's designation status at consultation.

What designated facilities deliver versus what marketing-only clinics promise

The substantive distinction between a designated facility operating under the Act and a clinic borrowing the regenerative-medicine terminology for marketing purposes shows up at consultation. A designated facility will identify itself as such, will name the designation tier (Institution or Center), will produce documentation of the designation at request, and will distinguish at consultation between therapies that fall within the Act's scope and adjacent therapies (such as exosome topical applications or generic growth-factor boosters) that do not. The protocol consent documentation will reference the risk-level classification of the therapy being proposed and will document the institutional-review-committee approval where applicable. The patient-safety monitoring structure will include scheduled follow-up at defined intervals, photo-documented baseline and progress imaging, a coordinated channel for adverse-event reporting in the patient's working language, and a documented escalation pathway if an unexpected response occurs. A clinic marketing regenerative-medicine packages without designation status will typically deliver a generic exosome-and-microneedling protocol, will not be able to produce documentation of facility-level designation, and will not reference the Act's classification scheme at consultation. The marketing protocol may still produce competent cosmetic results within its actual clinical lane — exosome and growth-factor protocols delivered via micro-channelling are widely available and substantively beneficial — but the patient should not be paying a premium positioned on a regulatory framework the clinic does not operate under.

Cell processing, source documentation, and what international patients should ask

Where cell-derived products are processed off-site at a separate licensed facility before delivery to the treating clinic, the Act requires documentation of the processing facility, the source-cell origin, the manipulation procedure, the quality-control protocols applied to the product, and the chain-of-custody from processing to delivery. International patients booking therapies that involve processed cell products should ask for this documentation at consultation; serious clinics provide it without prompting. The Korea Health Industry Development Institute (KHIDI) maintains the medical-tourism facilitator framework under which international patients access Korean regenerative practice, and KHIDI documentation of the facilitator (such as the registration number our operating entity carries, A-2026-04-02-06873) provides one additional verification layer on the operations side. Patients seeking depth on a specific cell product can cross-reference the manufacturer or processor against MFDS clearance records and against the published research literature on the same product class. Where the clinic declines to identify the processor or the source-cell origin, the patient is receiving a generic product behind branded packaging; this is not necessarily clinically inferior, but it is materially different from what the Act-framework presentation suggests.

Geographic clustering of designated facilities

Designated Advanced Regenerative Medical Institutions cluster in the Gangnam clinical district — particularly along the Apgujeong, Cheongdam, and Sinsa axis — with smaller numbers of designated facilities in central Seoul and a handful in regional cities. The geographic clustering reflects the broader concentration of senior dermatologic and aesthetic-medicine practice in the Gangnam belt, the infrastructure-density required to support designated-facility operations (dedicated cell-processing rooms, institutional-review-committee infrastructure, dedicated regenerative-medicine clinical personnel), and the patient-volume necessary to sustain the operational overhead. Patients booking regenerative-medicine work in [the Gangnam belt](/by-region/gangnam/) have the deepest selection of designated facilities; patients booking in [the Myeongdong belt](/by-region/myeongdong/) have access to a smaller designated-facility subset alongside a broader population of non-designated clinics delivering adjacent regenerative-adjacent protocols. For comprehensive regional context on regenerative practice across Korea, our [Korea-wide regional page](/by-region/korea/) treats the broader geographic distribution, and the broader visitor-side medical-tourism reference covers the editorial framework we apply to international-patient operations more generally.

Patient-safety monitoring, adverse-event reporting, and what to expect post-procedure

The Act requires designated facilities to operate a patient-safety monitoring structure that runs from the consultation through the post-procedure follow-up window and beyond. Conventional protocol structure includes documented consent that references the risk-level classification of the therapy and any institutional-review-committee approval; baseline-photo documentation at consultation; a defined follow-up schedule (commonly at week one, week four, and month three for the initial programme); a coordinated patient-channel in the patient's working language for the acute monitoring window; an adverse-event reporting structure that captures both clinically expected reactions and unexpected responses; and an escalation pathway to senior physician review for any unexpected events. International patients should expect this structure at a designated facility; absence of any of these elements at a clinic claiming designation status warrants verification. Conventional expected reactions in regenerative protocols include transient erythema, mild oedema, and pinpoint bleeding at microneedling or RF-assisted-channelling entry sites; these resolve within 48 to 72 hours. Unexpected responses — sustained erythema beyond a week, nodule formation, or asymmetric response — warrant clinic review and, where appropriate, escalation under the Act's adverse-event reporting framework. The Korea Tourism Organization medical-tourism portal maintains broader patient-orientation resources on Korean medical-tourism standards.

Pricing structure under the Act framework and what international patients should expect

Regenerative-medicine protocols at designated facilities in Korea typically range from KRW 800,000 to KRW 4,500,000 per session for entry-tier autologous protocols and from KRW 3,000,000 to KRW 12,000,000 or more per programme for medium-risk and higher-tier therapies, with multi-session programmes spanning two to four months and maintenance schedules every six to twelve months thereafter. The pricing spread reflects the cell-product cost (processed allogeneic products carry materially higher unit cost than autologous minimal-manipulation products), the institutional infrastructure overhead (designated facilities maintain dedicated cell-processing space and clinical personnel whose cost flows into the protocol price), and the senior-physician seniority premium that scales with documented regenerative-medicine experience. Patients comparing prices across clinics should compare like-for-like protocols — a 'stem cell' label across two clinics may denote materially different products with materially different regulatory status — and should weight designation-status documentation as a substantive factor in the comparison. Cross-reference our [pricing-guide reference](/pricing-guide/) for the broader Korean aesthetic-pricing context and the [treatments overview](/treatments/) for the categorical framework. Patients booking through medical-tourism facilitators should verify that the quoted price reflects the protocol-and-product combination disclosed at consultation; substitution of a lower-tier product post-booking is not common at designated facilities but warrants verification.

Frequently asked questions

What does the Advanced Regenerative Medicine Act actually regulate?

The Act, in force since August 2020, regulates the delivery of cell-derived therapies in Korea through a tiered facility-designation system and a risk-level classification of the therapies themselves. It establishes which facilities may deliver which classes of regenerative therapy, what protocol documentation is required, what patient-safety monitoring must be maintained, and what adverse-event reporting framework applies. Cell-derived therapies outside the Act's scope, such as topical exosome applications, follow conventional cosmetic-product regulation under MFDS frameworks rather than the Act.

How do I verify that a clinic operates as a designated facility under the Act?

Ask at consultation. Designated facilities will identify themselves as such, name the designation tier (Advanced Regenerative Medical Institution or Advanced Regenerative Medicine Center), and produce documentation at request. The institutional designation is verifiable through Ministry of Health and Welfare records. Clinics that decline to specify or use generic regenerative-medicine terminology without naming a designation tier are most likely operating outside the Act's framework and delivering adjacent therapies under conventional cosmetic-product regulation.

Are non-designated clinics necessarily inferior?

Not necessarily, and the framing matters. A non-designated clinic delivering a competent exosome-and-microneedling protocol may produce substantively similar cosmetic outcomes to a designated facility delivering an autologous low-risk protocol, in the same clinical lane. The substantive difference shows up where the therapy proposed nominally falls under the Act's scope — medium-risk or high-risk allogeneic or substantially manipulated cell products — and the clinic delivering it lacks the corresponding designation. The patient is then paying a premium positioned on a regulatory framework the clinic does not operate under.

What documentation should I receive at consultation?

At a designated facility, expect: consent documentation that references the risk-level classification of the proposed therapy; documentation of the processing facility for any off-site-processed cell product; documentation of the source-cell origin where applicable; documentation of institutional-review-committee approval for therapies requiring it; baseline-photo documentation; a defined follow-up schedule; an adverse-event reporting protocol summary in your working language; and the facility's designation reference. Absence of any of these elements at a clinic claiming designation status warrants verification before consenting.

How does the Act framework affect international patients specifically?

International patients receive care at designated facilities under the same regulatory framework that applies to domestic patients; the Act does not establish a separate pathway for foreign-national patients. The medical-tourism facilitator framework administered by the Korea Health Industry Development Institute (KHIDI) operates above the Act and structures how international patients access Korean medical care, including registered facilitator status for intermediaries operating in the market. Patients booking through KHIDI-registered facilitators (such as our operating entity, A-2026-04-02-06873) receive an additional verification layer on the operations side.

What happens if an adverse event occurs during or after the protocol?

Designated facilities operate under a structured adverse-event reporting framework that captures both clinically expected reactions and unexpected responses, with documented escalation pathways to senior-physician review and to Ministry reporting where the event warrants it. International patients should expect a coordinated channel in their working language during the acute monitoring window, with documented review at scheduled follow-up intervals. Patients experiencing unexpected responses should contact the treating clinic directly through the coordinator channel rather than attempting self-management.

How does the Act framework relate to the MFDS device and drug clearance system?

The Act operates in parallel with the conventional MFDS clearance pathways for medical devices and pharmaceutical products. Devices used in regenerative protocols (microneedling devices, RF-assisted-channelling platforms) follow MFDS device-clearance regulation; pharmaceutical and biological products follow MFDS drug-and-biologic regulation; cell-derived therapies that fall within the Act's scope follow the Act's specific designation and classification framework. Many regenerative protocols therefore involve products from all three regulatory streams, and a substantive consultation will clarify which regulatory framework applies to which element of the proposed protocol.

How long has the Act been in effect, and is the framework stable?

The Act has been in effect since August 2020, with implementing regulations refined through subsequent Ministry guidance. The framework is structurally stable, with periodic updates to specific designation criteria and risk-level classifications as the underlying clinical science develops. International patients booking regenerative protocols in Korea operate under the current framework; significant framework revisions would be announced through Ministry of Health and Welfare channels and would not retroactively affect protocols delivered under prior framework guidance.